Innovent Biologics Wins China Reimbursement for Seven Products, Including Mazdutide and PECONDLE

Innovent Biologics said seven of its innovative products were included in China's updated 2026 National Reimbursement Drug List, taking its reimbursed innovative drug lineup to 17 products that have cumulatively benefited over 20 million patients. The Suzhou-based, Hong Kong-listed company announced the inclusions on November 14, 2026, according to PR Newswire.

What Innovent Added to the 2026 List

Four products enter the list for the first time: mazdutide, a GCG/GLP-1 dual receptor agonist; PECONDLE (picankibart injection), an IL-23p19 inhibitor; TABOSUN (Ipilimumab N01 injection), a CTLA-4 inhibitor; and Vanflyta (quizartinib), a Type II FLT3 inhibitor. Mazdutide is covered for type 2 diabetes in adults, and PECONDLE for adults with moderate to severe plaque psoriasis eligible for systemic therapy. TABOSUN is covered in combination with sintilimab for the neoadjuvant treatment of resectable stage IIB-III MSI-H or dMMR colon cancer, and Vanflyta for newly diagnosed FLT3-ITD positive acute myeloid leukemia.

TYVYT (sintilimab injection) and Jaypirca (pirtobrutinib) gain new indications, while SINTBILO (tafolecimab injection) was renewed. The updated list takes effect on January 1, 2027. "The inclusion of the innovative drugs in the NRDL will further enhance the accessibility and affordability for patients, allowing more of the public to benefit," said Dr. Michael Yu, Innovent's founder, chairman and CEO.

Innovent's Deal Record Behind the Portfolio

Innovent is a Suzhou-headquartered biopharmaceutical company developing and commercializing biologics across oncology, metabolic, autoimmune and ophthalmic disease, according to akta.pro company records. The same records list a May 2026 global licensing and collaboration agreement with Pfizer worth up to $10.5 billion, with $650 million upfront and up to $9.85 billion in milestones, covering 12 early-stage cancer medicines.

Earlier Steps Toward the Listing

On October 7, 2026, Simply Wall St reported that Innovent received NMPA approval for Jaypirca in CLL/SLL. On October 19, 2026, AETOSWire reported that Takeda entered a license and collaboration agreement with Innovent for two late-stage oncology medicines, IBI363 and IBI343, worldwide outside Greater China. On November 10, 2026, In Vivo reported that the European Medicines Agency's CHMP was considering approval for seven new products and re-examining two previously rejected medicines, with Innovent awaiting the EMA's verdict on sintilimab.

When the Coverage Begins

The updated National Reimbursement Drug List takes effect on January 1, 2027.